269 related articles for article (PubMed ID: 25456560)
1. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
Turncliff R; DiPetrillo L; Silverman B; Ehrich E
Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):442-8. PubMed ID: 27137716
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):434-41. PubMed ID: 27137715
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Sun L; McDonnell D; von Moltke L
Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
[TBL] [Abstract][Full Text] [Related]
7. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
8. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
9. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
[TBL] [Abstract][Full Text] [Related]
10. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
[TBL] [Abstract][Full Text] [Related]
11. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Sun L; Yagoda S; Yao B; Graham C; von Moltke L
Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
[TBL] [Abstract][Full Text] [Related]
12. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers.
Fukumura K; Yokota T; Baba Y; Arjona Ferreira JC
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):474-483. PubMed ID: 28960888
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
Gottfridsson C; Carlson G; Lappalainen J; Sostek M
Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
[TBL] [Abstract][Full Text] [Related]
16. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.
Yuan CS; Doshan H; Charney MR; O'connor M; Karrison T; Maleckar SA; Israel RJ; Moss J
J Clin Pharmacol; 2005 May; 45(5):538-46. PubMed ID: 15831777
[TBL] [Abstract][Full Text] [Related]
17. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of samidorphan, a μ-opioid antagonist, in a drug discrimination assay in rats.
Sgro MP; Modlin DL; Deaver DR; Kallman MJ; Todtenkopf MS
Drug Dev Res; 2018 Aug; 79(5):234-238. PubMed ID: 30188587
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
Lowe SL; Wong CJ; Witcher J; Gonzales CR; Dickinson GL; Bell RL; Rorick-Kehn L; Weller M; Stoltz RR; Royalty J; Tauscher-Wisniewski S
J Clin Pharmacol; 2014 Sep; 54(9):968-78. PubMed ID: 24619932
[TBL] [Abstract][Full Text] [Related]
20. Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist.
Shram MJ; Silverman B; Ehrich E; Sellers EM; Turncliff R
J Clin Psychopharmacol; 2015 Jun; 35(3):242-9. PubMed ID: 25928699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
